SCHEMBL4306377

SCHEMBL4306377

CCCC#Cc1cccc(C(=O)C(=O)c2ccc(OC(F)F)c(C3CC3)c2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 10/20 0.38
PDE4B Q07343 9/20 0.38
PDE4A P27815 8/20 0.38
PDE4C Q08493 8/20 0.38
REN P00797 1/20 0.37
CTSD P07339 1/20 0.37
BACE1 P56817 1/20 0.37
BACE2 Q9Y5Z0 1/20 0.37
HAO1 Q9UJM8 1/20 0.35
CYP2D6 P10635 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
PTPN2 P17706 1/20 0.33
PTPN1 P18031 1/20 0.33
PTPN6 P29350 1/20 0.33
PTPN11 Q06124 1/20 0.33
MRGPRX4 Q96LA9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4306019 0.92 PDE4D (0.37) PDE4DPDE4BPDE4APDE4CBACE1
SCHEMBL4308354 0.91 BACE1 (0.39) PDE4DPDE4BPDE4APDE4CREN
SCHEMBL4315734 0.90 PDE4B (0.37) PDE4DPDE4BPDE4APDE4CREN
SCHEMBL4310778 0.89 BACE1 (0.37) PDE4DPDE4BPDE4APDE4CBACE1
SCHEMBL4309481 0.89 PTPN2 (0.36) PDE4DPDE4BPDE4APDE4CREN
SCHEMBL4308365 0.88 BACE1 (0.37) PDE4DPDE4BPDE4APDE4CREN
SCHEMBL4305817 0.87 PDE4D (0.36) PDE4DPDE4BPDE4APDE4CMEN1
SCHEMBL4308458 0.85 PDE4D (0.37) PDE4DPDE4BPDE4APDE4CREN
SCHEMBL4304207 0.84 BACE1 (0.41) PDE4DPDE4BPDE4APDE4CREN
SCHEMBL4312770 0.83 LMNA (0.41) PDE4DPDE4BPDE4APDE4CHAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP PDE4D 955/4885PDE4B 702/4885PDE4A 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.